THE APEX TIMES
Johnson & Johnson is featured in a new forecast for the atrial fibrillation treatment devices market through 2035
A market outlook highlighted growth drivers including aging populations, demand for less invasive and drug-free care, and technology shifts such as pulsed field ablation, advanced cardiac mapping tools, and left atrial appendage closure devices.
A new industry forecast for atrial fibrillation treatment devices projects growth opportunities through 2035, with Johnson & Johnson listed among the companies profiled in the report. The segment focuses on medical devices used to detect and treat irregular heart rhythms, including technologies intended to reduce reliance on long-term drug therapy.
The Yahoo Finance-distributed report points to aging populations and rising demand for safer, drug-free treatment approaches as key drivers for the category. It also points to procedural migration, highlighting ambulatory procedures and broader adoption across markets as contributors to demand.
Technology trends in the outlook center on pulsed field ablation, a type of energy-based heart ablation designed to treat abnormal electrical pathways while aiming to improve safety and effectiveness. The report also emphasizes advanced mapping catheters, which guide clinicians during electrophysiology procedures by mapping the heart’s electrical activity more precisely.
In addition to ablation and mapping tools, the forecast highlights left atrial appendage closure (LAAC) implants. These devices are used to reduce stroke risk in certain atrial fibrillation patients by addressing the left atrial appendage, an area where blood clots can form. The outlook groups these device categories together as part of an expanding treatment ecosystem.
The report also flags geographic expansion as a theme, calling out Asia-Pacific market growth and the role of increased access to advanced cardiac procedures. For device makers, such distribution and adoption dynamics often determine how quickly new procedures and technologies scale beyond leading hospitals.
Johnson & Johnson’s inclusion in the profiles suggests the report considers the company a relevant player in the competitive landscape, though the published Yahoo Finance post does not provide specific details about J&J’s product lines, revenue exposure, or any named product launches. The post likewise does not disclose what share of the market the company is expected to hold, or what portion of its healthcare business is tied to atrial fibrillation devices.
Still, the market narrative aligns with broader industry priorities for cardiology device companies: improving procedure precision, expanding the patient population that can undergo interventions, and offering alternatives to chronic medication management. The outlook’s emphasis on energy-based ablation and mapping, paired with LAAC implants, reflects a multi-pronged approach to managing atrial fibrillation complications.
For readers tracking the sector, the next practical questions will be whether technology adoption remains concentrated in specialized centers or broadens into more routine outpatient settings, and how quickly clinicians move toward pulsed field ablation and next-generation mapping tools. The Yahoo Finance post does not provide timetables, trial results, or adoption metrics, so investors and industry observers will likely look for more granular disclosures from the underlying market report or from device companies’ own filings and product updates.
Why It Matters
- Atrial fibrillation remains a large and growing cardiology need, and device makers compete on safer, more targeted interventions that can reduce dependence on medication.
- If pulsed field ablation and improved mapping continue to be adopted, manufacturers with relevant platforms may benefit from procedure growth and technology replacement cycles.
- LAAC implants connect atrial fibrillation rhythm management to stroke prevention, potentially broadening the addressable market for cardiology devices.
- The report’s market framing suggests attention will stay on outpatient-friendly pathways and regional expansion, factors that can influence device utilization rates.
Sources
Key Facts
- The atrial fibrillation treatment devices market forecast runs through 2035 and is distributed via Yahoo Finance.
- The report lists Johnson & Johnson among the companies profiled.
- Growth drivers cited include aging populations and demand for safer, drug-free treatment options.
- Technology trends highlighted include pulsed field ablation, advanced cardiac mapping catheters, and left atrial appendage closure (LAAC) implants.
- The outlook mentions procedural shifts such as ambulatory procedures and geographic expansion, including Asia-Pacific growth.
Healthcare Related
Eli Lilly shares keep rising even as drug prices trend lower, according to market commentary
A market-focused post points to optimism around Eli Lilly’s demand and distribution momentum as pricing pressure continues, but notes management has already indicated net prices will go lower from here.
Atrial fibrillation market forecast through 2035 highlights widening therapy mix, including investigational monoclonal antibody approach
A market outlook published by Yahoo Finance on Aug. 26, 2026 places antiarrhythmic agents at the center of current atrial fibrillation treatment while pointing to monoclonal antibodies as an emerging, still-investigational direction. The article’s company round-up includes Johnson & Johnson alongside Abbott, Boston Scientific, Medtronic, Novartis and Sanofi.
mRNA Therapeutics Market Outlook report points to expanding oncology and rare-disease pipelines through 2035, with Moderna among profiled companies
A new market outlook study published via Globe Newswire projects growth in mRNA therapeutics driven by oncology and rare-disease development efforts, delivery-technology advances, and partnerships, profiling Moderna alongside peers including BioNTech and CureVac.
Eli Lilly expands Alzheimer’s research collaboration with BioArctic as it builds obesity-related cost data
The company agreed a new research and collaboration deal with BioArctic, aiming to use the Swedish biotech’s BrainTransporter technology in a potential Alzheimer’s treatment, according to a report on Yahoo Finance.
Eli Lilly shares draw attention after study links Zepbound use to lower healthcare spending in older adults
A new analysis discussed in market coverage found monthly healthcare costs declined over time for adults over 55, with results suggesting reductions of up to 38 percent among those using Zepbound. The researchers said the models did not include the cost of Zepbound itself.
David Tepper fully exited UnitedHealth in Q2, but investors are left to read the tea leaves
A report says hedge fund billionaire David Tepper sold all of his UnitedHealth position during the second quarter. The move could be a routine portfolio adjustment, a valuation call, or a risk-management step, but the public record described in the article does not offer clear guidance on motive.
